Jordi Esteve

Jordi Esteve, MD, PhD is Head of the Acute Leukemia Unit at Hospital Clínic de Barcelona and Professor of Hematology at the University of Barcelona. He is the leading figure in adult ALL research within the Spanish PETHEMA (Programa Español de Tratamientos en Hematología) cooperative group and a recognized international authority on Ph-like ALL and targeted therapy integration. Dr. Esteve's group has been at the forefront of implementing genomic testing for Ph-like ALL subtypes in the clinical setting, establishing workflows for real-time kinase alteration profiling that can guide enrollment to targeted therapy trials. He has led Spanish and European studies evaluating ruxolitinib (a JAK1/2 inhibitor) in combination with standard chemotherapy for patients with CRLF2-rearranged or JAK-mutated Ph-like ALL, contributing pivotal data on the clinical activity and optimal integration of JAK inhibition in this subtype. Dr. Esteve also leads PETHEMA ALL trials examining MRD-guided risk stratification, including prospective evaluation of flow cytometry and molecular MRD as predictors of relapse and guides to allogeneic SCT decisions. His translational research has contributed to understanding clonal evolution in ALL relapse and resistance mechanisms to targeted agents, providing the scientific basis for combination strategies to overcome resistance.